Revolutionizing Asthma Treatment: Implementing ICS-Based Reliever Therapies in Clinical Practice

This live, virtual 1 hour Category I ACCME educational program, for primary care and specialty healthcare professionals, is intended to provide learners with an understanding of inhaled corticosteroid-based reliever therapeutic approaches for the management of adult asthma. 

Background: ß2 agonists like albuterol have been used for more than 50 years as the main reliever to treat acute asthma symptoms. Overuse of albuterol is extensive and is now well-documented this strategy is associated with poor outcomes. Clinical studies now support using an inhaled anti-inflammatory steroid when using a reliever like albuterol or formoterol, to better target the underlying inflammation present with symptoms. Inhaled corticosteroid-based reliever therapy is now recommended by the GINA and the US NAEPP guidelines. This represents a paradigm change for prescribers and patients, which requires extensive education efforts.  

Target Audience: Primary care and specialty providers involved in the chronic or acute management of persons with adult asthma.  

1. Understand the clinical science supporting prescribing an inhaled steroid with reliever bronchodilators
2. Discuss current practices employing albuterol reliever inhalers in asthma management and opportunities for change
3. Describe and utilize the current GINA and NAEPP recommendations for using AIR Therapy in asthma management
4. Discuss patient cases employing AIR therapy in asthma
5. Understand and use the clinical science and practical application of AIR Therapy in adults with asthma.